JPMorgan ups HilleVax target, adds to Analyst Focus List

JPMorgan raised the firm’s price target on HilleVax to $24 from $21 and keeps an Overweight rating on the shares. The analyst also added the stock to the firm’s Analyst Focus List and placed it on “Positive Catalyst Watch.” JPMorgan sees a positive reward/risk skew into the NEST-IN1 readout “with avenues for HIL-214 optionality on positive data.” HIL-214 is HilleVax’s vaccine candidate for norovirus-related illness in infants. The firm sees a “sizeable, readily accessible commercial opportunity, with a straightforward pivotal development path.”